

# Hiroyuki Shimada

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12331/publications.pdf>

Version: 2024-02-01

153  
papers

11,413  
citations

50276

46  
h-index

29157

104  
g-index

154  
all docs

154  
docs citations

154  
times ranked

8361  
citing authors

#	ARTICLE	IF	CITATIONS
1	Low-concentration povidone-iodine for the prevention of intraocular infections in ophthalmic surgery. <i>Current Opinion in Ophthalmology</i> , 2022, 33, 28-34.	2.9	5
2	Genetic and Histopathological Heterogeneity of Neuroblastoma and Precision Therapeutic Approaches for Extremely Unfavorable Histology Subgroups. <i>Biomolecules</i> , 2022, 12, 79.	4.0	12
3	Safety Measures for Maintaining Low Endophthalmitis Rate after Intravitreal Anti-Vascular Endothelial Growth Factor Injection before and during the COVID-19 Pandemic. <i>Journal of Clinical Medicine</i> , 2022, 11, 876.	2.4	7
4	Bilateral Pachychoroid disease with type 3 Uveal effusion syndrome in one eye and central serous Chorioretinopathy in contralateral eye: a case report. <i>BMC Ophthalmology</i> , 2022, 22, 91.	1.4	4
5	One-Year Outcome of Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injections for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy. <i>Journal of Clinical Medicine</i> , 2022, 11, 2175.	2.4	4
6	Macrophage-mediated anti-tumor immunity against high-risk neuroblastoma. <i>Genes and Immunity</i> , 2022, 23, 129-140.	4.1	6
7	Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2022, 40, 4107-4118.	1.6	11
8	Combined immune checkpoint blockade increases CD8+CD28+PD-1+ effector T cells and provides a therapeutic strategy for patients with neuroblastoma. <i>Oncolmmunology</i> , 2021, 10, 1838140.	4.6	22
9	Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma. <i>Nature Communications</i> , 2021, 12, 511.	12.8	85
10	Clinical Relevance of CD4 Cytotoxic T Cells in High-Risk Neuroblastoma. <i>Frontiers in Immunology</i> , 2021, 12, 650427.	4.8	11
11	Changes in ctDNA levels after MIBG therapy in patients with relapsed or refractory neuroblastoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 10012-10012.	1.6	1
12	Large cell neuroblastoma â€“ Phenotypical variant of MYC-driven neuroblastoma: Report of 2 cases with different molecular characteristics. <i>Human Pathology: Case Reports</i> , 2021, 24, 200493.	0.2	2
13	Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2021, 39, 3229-3241.	1.6	174
14	Combining inhibitors of Brd4 and cyclin-dependent kinase can decrease tumor growth in neuroblastoma with MYCN amplification. <i>Journal of Pediatric Surgery</i> , 2021, 56, 1199-1202.	1.6	9
15	Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium. <i>Journal of Clinical Oncology</i> , 2021, 39, 3506-3514.	1.6	38
16	Cataract Surgery by Intraoperative Surface Irrigation with 0.25% Povidoneâ€“Iodine. <i>Journal of Clinical Medicine</i> , 2021, 10, 3611.	2.4	13
17	A unique composite tumour of the adrenal gland in a paediatric patient, with adrenal cortical and neural crest cell-like components. <i>Pathology</i> , 2021, 53, 668-670.	0.6	0
18	A case of bilateral pachychoroid disease: polypoidal choroidal vasculopathy in one eye and peripheral exudative hemorrhagic chorioretinopathy in contralateral eye. <i>BMC Ophthalmology</i> , 2021, 21, 320.	1.4	1

#	ARTICLE	IF	CITATIONS
19	Stage 4S Neuroblastoma. American Journal of Surgical Pathology, 2021, 45, 1075-1081.	3.7	10
20	Composite Neuroblastoma Metastatic to a Lymph Node: The Novel Histopathologic Diagnosis of a Unique Multiclonal Neoplasm. Annals of Clinical and Laboratory Science, 2021, 51, 573-579.	0.2	0
21	Age Inherently Links to Histology to Define Histoprognostic Classification of Peripheral Neuroblastic Tumors. Journal of Clinical Oncology, 2020, 38, 3719-3720.	1.6	1
22	MYC transcription activation mediated by OCT4 as a mechanism of resistance to 13-cisRA-mediated differentiation in neuroblastoma. Cell Death and Disease, 2020, 11, 368.	6.3	18
23	The Role of the Clinical Laboratory in the Diagnosis of Neuroblastoma. journal of applied laboratory medicine, The, 2020, 5, 254-256.	1.3	0
24	Association of heterogeneous MYCN amplification with clinical features, biological characteristics and outcomes in neuroblastoma: A report from the Children's Oncology Group. European Journal of Cancer, 2020, 133, 112-119.	2.8	13
25	Enhancing sustained-release local therapy: Single versus dual chemotherapy for the treatment of neuroblastoma. Surgery, 2020, 167, 969-977.	1.9	4
26	Foveal avascular zone area analysis in juvenile-onset type 1 diabetes using optical coherence tomography angiography. Japanese Journal of Ophthalmology, 2020, 64, 271-277.	1.9	15
27	Local delivery of dinutuximab from lyophilized silk fibroin foams for treatment of an orthotopic neuroblastoma model. Cancer Medicine, 2020, 9, 2891-2903.	2.8	11
28	Combined Replenishment of miR-34a and let-7b by Targeted Nanoparticles Inhibits Tumor Growth in Neuroblastoma Preclinical Models. Small, 2020, 16, e1906426.	10.0	27
29	Abstract 1293: MYC transcription activation mediated by OCT4 as a mechanism of resistance to 13-cisRA-mediated differentiation in neuroblastoma. , 2020, , .		0
30	Pathology of Peripheral Neuroblastic Tumors. Clinical Pediatric Hematology-Oncology, 2020, 27, 73-86.	0.2	2
31	Intraocular lens implantation and vitrectomy using 0.025% povidone-iodine in irrigation solution for bleb-related endophthalmitis. International Journal of Ophthalmology, 2020, 13, 1499-1502.	1.1	0
32	Pioneer in Pediatric Pathology: William A (Bill) Newton Jr (1923-2019). Pediatric and Developmental Pathology, 2019, 22, 91-97.	1.0	2
33	Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531. Journal of Clinical Oncology, 2019, 37, 3243-3255.	1.6	61
34	Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study. Clinical Cancer Research, 2019, 25, 6044-6051.	7.0	20
35	No increase in incidence of post-intravitreal injection endophthalmitis without topical antibiotics: a prospective study. Japanese Journal of Ophthalmology, 2019, 63, 396-401.	1.9	7
36	Replicating and identifying large cell neuroblastoma using high-dose intra-tumoral chemotherapy and automated digital analysis. Journal of Pediatric Surgery, 2019, 54, 2595-2599.	1.6	1

#	ARTICLE	IF	CITATIONS
37	Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells. <i>Clinical Cancer Research</i> , 2019, 25, 4761-4774.	7.0	53
38	Down-regulation of MYCN protein by CX-5461 leads to neuroblastoma tumor growth suppression. <i>Journal of Pediatric Surgery</i> , 2019, 54, 1192-1197.	1.6	18
39	Intravitreal Injection of 1.25% Povidone Iodine Followed by Vitrectomy Using 0.025% Povidone Iodine Irrigation for Treating Endophthalmitis. <i>Translational Vision Science and Technology</i> , 2019, 8, 21.	2.2	15
40	Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531. <i>Journal of Clinical Oncology</i> , 2019, 37, 115-124.	1.6	45
41	Subgrouping of Unfavorable Histology Neuroblastomas With Immunohistochemistry Toward Precision Prognosis and Therapy Stratification. <i>JCO Precision Oncology</i> , 2019, 3, 1-7.	3.0	9
42	Relationship of Area of Soft Drusen in Retina with Cerebral Amyloid- $\beta^2$ Accumulation and Blood Amyloid- $\beta^2$ Level in the Elderly. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 239-245.	2.6	7
43	Histologic and ultrastructural features in early and advanced phases of Zellweger spectrum disorder (infantile Refsum disease). <i>Ultrastructural Pathology</i> , 2018, 42, 220-227.	0.9	11
44	Rare MYC-amplified Neuroblastoma With Large Cell Histology. <i>Pediatric and Developmental Pathology</i> , 2018, 21, 461-466.	1.0	11
45	Predictors of response, progression-free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high-risk neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26940.	1.5	10
46	Capsular bag irrigation using 0.025% povidone-iodine in balanced salt solution PLUS for the treatment of postoperative endophthalmitis. <i>International Ophthalmology</i> , 2018, 38, 1787-1790.	1.4	7
47	Cytologic and Ultrastructural Findings of Bronchoalveolar Lavage in Patients With Chronic Granulomatous Disease. <i>Pediatric and Developmental Pathology</i> , 2018, 21, 347-354.	1.0	4
48	Utility of Phox2b immunohistochemical stain in neural crest tumours and non-neural crest tumours in paediatric patients. <i>Histopathology</i> , 2018, 72, 685-696.	2.9	22
49	Capsular bag irrigation using 0.025% povidone-iodine in balanced salt solution PLUS for the treatment of postoperative endophthalmitis. <i>International Ophthalmology</i> , 2018, 38, 2267-2268.	1.4	2
50	MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology group. <i>Oncotarget</i> , 2018, 9, 6416-6432.	1.8	31
51	Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis. <i>Clinical Cancer Research</i> , 2017, 23, 5374-5383.	7.0	38
52	Reduced anterior chamber contamination by frequent surface irrigation with diluted iodine solutions during cataract surgery. <i>Acta Ophthalmologica</i> , 2017, 95, e373-e378.	1.1	22
53	Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group. <i>Cancer</i> , 2017, 123, 1095-1105.	4.1	75
54	Contribution of neuroblastoma-derived exosomes to the production of pro-tumorigenic signals by bone marrow mesenchymal stromal cells. <i>Journal of Extracellular Vesicles</i> , 2017, 6, 1332941.	12.2	47

#	ARTICLE	IF	CITATIONS
55	Re: Merani et al.: Aqueous chlorhexidine for intravitreal injection antiseptics ( Ophthalmology.) Tj ETQq1 1 0.784314 5.25 / Overlock 10	5.25	10
56	Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. Cancer, 2017, 123, 4224-4235.	4.1	97
57	Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells. Cancer Research, 2017, 77, 5142-5157.	0.9	130
58	Implantable chemotherapy-loaded silk protein materials for neuroblastoma treatment. International Journal of Cancer, 2017, 140, 726-735.	5.1	35
59	Association of high microvessel density and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126. Oncotarget, 2017, 8, 52193-52210.	1.8	24
60	Tumor-associated macrophages promote neuroblastoma via STAT3 phosphorylation and up-regulation of c-MYC. Oncotarget, 2017, 8, 91516-91529.	1.8	45
61	Am80's GCSF synergizes myeloid expansion and differentiation to generate functional neutrophils that reduce neutropenia-associated infection and mortality. EMBO Molecular Medicine, 2016, 8, 1340-1359.	6.9	10
62	The clinical management and outcomes of cervical neuroblastic tumors. Journal of Surgical Research, 2016, 204, 109-113.	1.6	20
63	Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database. European Journal of Cancer, 2016, 65, 1-10.	2.8	56
64	Reactive Oxygen Species Mediates the Synergistic Activity of Fenretinide Combined with the Microtubule Inhibitor ABT-751 against Multidrug-Resistant Recurrent Neuroblastoma Xenografts. Molecular Cancer Therapeutics, 2016, 15, 2653-2664.	4.1	20
65	Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injection for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy. Ophthalmology, 2016, 123, 1278-1286.	5.2	30
66	Phase II study of alisertib, irinotecan, and temozolomide in children with relapsed and refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy (NANT) consortium.. Journal of Clinical Oncology, 2016, 34, 10556-10556.	1.6	0
67	Human and mouse tissue-engineered small intestine both demonstrate digestive and absorptive function. American Journal of Physiology - Renal Physiology, 2015, 308, G664-G677.	3.4	88
68	Exosome-Mediated Transfer of microRNAs Within the Tumor Microenvironment and Neuroblastoma Resistance to Chemotherapy. Journal of the National Cancer Institute, 2015, 107, .	6.3	298
69	Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma. Clinical Cancer Research, 2015, 21, 2715-2721.	7.0	62
70	A feasibility and phase II study of the hu14.18-IL2 immunocytokine in combination with GM-CSF and isotretinoin in patients with recurrent or refractory neuroblastoma: A Children's Oncology Group study.. Journal of Clinical Oncology, 2015, 33, 10017-10017.	1.6	7
71	Age-Dependent Prognostic Effect by Mitosis-Karyorrhexis Index in Neuroblastoma: A Report from the Children's Oncology Group. Pediatric and Developmental Pathology, 2014, 17, 441-449.	1.0	35
72	MYCN-Dependent Expression of Sulfatase-2 Regulates Neuroblastoma Cell Survival. Cancer Research, 2014, 74, 5999-6009.	0.9	9

#	ARTICLE	IF	CITATIONS
73	Prophylaxis for acute scleral buckle infection using 0.25% povidone-iodine ocular surface irrigation during surgery. <i>International Ophthalmology</i> , 2014, 34, 211-216.	1.4	13
74	Validation of a prognostic multi-gene signature in high-risk neuroblastoma using the high throughput digital NanoString nCounter <sup>®</sup> system. <i>Molecular Oncology</i> , 2014, 8, 669-678.	4.6	32
75	Neuroblastoma or not neuroblastoma. <i>Human Pathology</i> , 2014, 45, 662-663.	2.0	0
76	Peripheral neuroblastic tumors with genotype-phenotype discordance: A report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee. <i>Pediatric Blood and Cancer</i> , 2013, 60, 363-370.	1.5	25
77	Transient treatment with epigenetic modifiers yields stable neuroblastoma stem cells resembling aggressive large-cell neuroblastomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 6097-6102.	7.1	50
78	Minimizing the endophthalmitis rate following intravitreal injections using 0.25% povidone-iodine irrigation and surgical mask. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , 2013, 251, 1885-1890.	1.9	71
79	Reducing bacterial contamination inside fluid catch bag in 25-gauge vitrectomy by use of 0.25% povidone-iodine ocular surface irrigation. <i>International Ophthalmology</i> , 2013, 33, 35-38.	1.4	5
80	Critical Role of STAT3 in IL-6-Mediated Drug Resistance in Human Neuroblastoma. <i>Cancer Research</i> , 2013, 73, 3852-3864.	0.9	109
81	Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYC <i>N</i> protein expression: A report from the Children's Oncology Group. <i>Cancer</i> , 2013, 119, 3718-3726.	4.1	67
82	REDUCTION OF VITREOUS CONTAMINATION RATE AFTER 25-GAUGE VITRECTOMY BY SURFACE IRRIGATION WITH 0.25% POVIDONE-IODINE. <i>Retina</i> , 2013, 33, 143-151.	1.7	18
83	Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) to predict outcome in patients with stage 4 disease: A study from the International Neuroblastoma (NB) Risk Group (INRG) Database.. <i>Journal of Clinical Oncology</i> , 2013, 31, 10015-10015.	1.6	0
84	Dose Escalation Study of No-Carrier-Added <sup>131</sup> I-Metaiodobenzylguanidine for Relapsed or Refractory Neuroblastoma: New Approaches to Neuroblastoma Therapy Consortium Trial. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1155-1163.	5.0	64
85	Phase I Study of Vincristine, Irinotecan, and <sup>131</sup> I-Metaiodobenzylguanidine for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial. <i>Clinical Cancer Research</i> , 2012, 18, 2679-2686.	7.0	69
86	Clinical Significance of Tumor-Associated Inflammatory Cells in Metastatic Neuroblastoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 3525-3532.	1.6	236
87	Characteristics and outcome of patients with ganglioneuroblastoma, nodular subtype: A report from the INRG project. <i>European Journal of Cancer</i> , 2012, 48, 1185-1191.	2.8	14
88	Clear Visualization of Anterior Vitreous Incarceration into Cannulae during 25-Gauge Vitrectomy in Eyes with Asteroid Hyalosis. <i>European Journal of Ophthalmology</i> , 2012, 22, 293-295.	1.3	3
89	Outcome After Surgery Alone or With Restricted Use of Chemotherapy for Patients With Low-Risk Neuroblastoma: Results of Children's Oncology Group Study P9641. <i>Journal of Clinical Oncology</i> , 2012, 30, 1842-1848.	1.6	174
90	Outcome analysis of non-high-risk neuroblastoma patients enrolled on Children's Oncology Group trials P9641 and A3961.. <i>Journal of Clinical Oncology</i> , 2012, 30, 9533-9533.	1.6	0

#	ARTICLE	IF	CITATIONS
91	Effect of insulin-like growth factor 2 gene expression on pleuropulmonary blastoma and embryonal rhabdomyosarcoma.. Journal of Clinical Oncology, 2012, 30, 9564-9564.	1.6	0
92	Genome-based outcome prediction in <i>MYCN </i>nonamplified high-risk neuroblastoma.. Journal of Clinical Oncology, 2012, 30, 9534-9534.	1.6	0
93	Depiction of the vitreous pocket by optical coherence tomography. International Ophthalmology, 2011, 31, 51-53.	1.4	10
94	EFFECT OF OPERATIVE FIELD IRRIGATION ON INTRAOPERATIVE BACTERIAL CONTAMINATION AND POSTOPERATIVE ENDOPHTHALMITIS RATES IN 25-GAUGE VITRECTOMY. Retina, 2010, 30, 1242-1249.	1.7	17
95	Highly viscous fluid in macular holes. International Ophthalmology, 2010, 30, 319-321.	1.4	4
96	Current Treatment Protocols Have Eliminated the Prognostic Advantage of Type 1 Fusions in Ewing Sarcoma: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2010, 28, 1989-1994.	1.6	138
97	Outcome after Reduced Chemotherapy for Intermediate-Risk Neuroblastoma. New England Journal of Medicine, 2010, 363, 1313-1323.	27.0	253
98	Adjuvant CD49d Blockade Eradicates Chemoresistant ALL. Blood, 2010, 116, 869-869.	1.4	7
99	Concentration Gradient of Vascular Endothelial Growth Factor in the Vitreous of Eyes with Diabetic Macular Edema. , 2009, 50, 2953.		51
100	Early onset of Rhegmatogenous retinal detachment after LASIK with femtosecond laser. Japanese Journal of Ophthalmology, 2009, 53, 75-76.	1.9	7
101	Transient increase in macular edema following vitrectomy for retinal branch vein occlusion. International Ophthalmology, 2009, 29, 95-98.	1.4	1
102	Bimanual anterior vitrectomy using a 25-gauge high-speed cutter to manage vitreous loss during phacoemulsification. International Ophthalmology, 2009, 29, 253-255.	1.4	2
103	Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: A report from the CCG and COG. Pediatric Blood and Cancer, 2009, 53, 563-569.	1.5	79
104	Double Staining with Brilliant Blue G and Double Peeling for Epiretinal Membranes. Ophthalmology, 2009, 116, 1370-1376.	5.2	151
105	Three-dimensional depiction of the vitreous pocket using triamcinolone acetonide. European Journal of Ophthalmology, 2009, 19, 1102-5.	1.3	4
106	Pathological findings of multifocal choroiditis with panuveitis and punctate inner choroidopathy. Japanese Journal of Ophthalmology, 2008, 52, 282-288.	1.9	55
107	Frequency, source, and prevention of cotton fibers in the anterior chamber during cataract surgery. Journal of Cataract and Refractive Surgery, 2008, 34, 1389-1392.	1.5	22
108	Incidence of Endophthalmitis after 20- and 25-Gauge Vitrectomy. Ophthalmology, 2008, 115, 2215-2220.	5.2	122

#	ARTICLE	IF	CITATIONS
109	Mouse Mesenchymal Stem Cells Expressing PAX-FKHR Form Alveolar Rhabdomyosarcomas by Cooperating with Secondary Mutations. <i>Cancer Research</i> , 2008, 68, 6587-6597.	0.9	102
110	Thermal Injury Caused by Chandelier Fiber Probe. <i>American Journal of Ophthalmology</i> , 2007, 143, 167-169.	3.3	12
111	IMAGE ANALYSIS FOR AUTOMATED ASSESSMENT OF GRADE OF NEUROBLASTIC DIFFERENTIATION. , 2007, , .		21
112	Computer-Aided Grading of Neuroblastic Differentiation: Multi-Resolution and Multi-Classifer Approach. , 2007, , .		17
113	Pathology of peripheral neuroblastic tumors: Significance of prominent nucleoli in undifferentiated/poorly differentiated neuroblastoma. <i>Pathology and Oncology Research</i> , 2007, 13, 269-275.	1.9	36
114	25-Gauge Scleral Tunnel Transconjunctival Vitrectomy. <i>American Journal of Ophthalmology</i> , 2006, 142, 871-873.	3.3	125
115	International neuroblastoma pathology classification adds independent prognostic information beyond the prognostic contribution of age. <i>European Journal of Cancer</i> , 2006, 42, 1113-1119.	2.8	63
116	Prognostic Significance of Gene Expression Profiles of Metastatic Neuroblastomas Lacking MYCN Gene Amplification. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1193-1203.	6.3	212
117	Does <i>MYCN</i> Amplification Manifested as Homogeneously Staining Regions at Diagnosis Predict a Worse Outcome in Children with Neuroblastoma? A Children's Oncology Group Study. <i>Clinical Cancer Research</i> , 2006, 12, 5693-5697.	7.0	35
118	Enlarged and prominent nucleoli may be indicative of MYCN amplification. <i>Cancer</i> , 2005, 103, 174-180.	4.1	38
119	Twenty-gauge Transconjunctival Vitrectomy. <i>Japanese Journal of Ophthalmology</i> , 2005, 49, 257-260.	1.9	12
120	Expanded Indications for 25-Gauge Transconjunctival Vitrectomy. <i>Japanese Journal of Ophthalmology</i> , 2005, 49, 397-401.	1.9	82
121	Surgical excision of neovascularization in retinal angiomatous proliferation. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2005, 243, 519-524.	1.9	18
122	In Situ Neuroblastoma: An Important Concept Related to the Natural History of Neural Crest Tumors. <i>Pediatric and Developmental Pathology</i> , 2005, 8, 305-306.	1.0	9
123	Favorable Prognosis for Patients 12 to 18 Months of Age With Stage 4 Nonamplified MYCN Neuroblastoma: A Children's Cancer Group Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 6474-6480.	1.6	133
124	Chromosome 1p and 11q Deletions and Outcome in Neuroblastoma. <i>New England Journal of Medicine</i> , 2005, 353, 2243-2253.	27.0	495
125	Large cell neuroblastoma. <i>Cancer</i> , 2004, 100, 390-397.	4.1	49
126	Revision of the International Neuroblastoma Pathology Classification. <i>Cancer</i> , 2003, 98, 2274-2281.	4.1	249



#	ARTICLE	IF	CITATIONS
127	Morphologic features of neuroblastoma (Schwannian stroma-poor tumors) in clinically favorable and unfavorable groups. <i>Cancer</i> , 2002, 94, 1574-1583.	4.1	49
128	Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: Histopathologic features-A report from the children's cancer group. <i>Medical and Pediatric Oncology</i> , 2001, 36, 623-629.	1.0	105
129	International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors. <i>Cancer</i> , 2001, 92, 2451-2461.	4.1	273
130	Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors. <i>Cancer</i> , 2001, 92, 2699-2708.	4.1	132
131	International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors. , 2001, 92, 2451.		3
132	Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors. , 2001, 92, 2699.		1
133	Histopathology defines prognostic subsets of ganglioneuroblastoma, nodular. <i>Cancer</i> , 2000, 89, 1150-1161.	4.1	47
134	Favorable Biology and Outcome of Stage IV-S Neuroblastoma With Supportive Care or Minimal Therapy: A Children's Cancer Group Study. <i>Journal of Clinical Oncology</i> , 2000, 18, 477-477.	1.6	243
135	Biologic Factors Determine Prognosis in Infants With Stage IV Neuroblastoma: A Prospective Children's Cancer Group Study. <i>Journal of Clinical Oncology</i> , 2000, 18, 1260-1268.	1.6	212
136	Biologic Variables in the Outcome of Stages I and II Neuroblastoma Treated With Surgery as Primary Therapy: A Children's Cancer Group Study. <i>Journal of Clinical Oncology</i> , 2000, 18, 18-18.	1.6	218
137	Terminology and morphologic criteria of neuroblastic tumors. <i>Cancer</i> , 1999, 86, 349-363.	4.1	583
138	The International Neuroblastoma Pathology Classification (the Shimada system). <i>Cancer</i> , 1999, 86, 364-372.	4.1	940
139	Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid. <i>New England Journal of Medicine</i> , 1999, 341, 1165-1173.	27.0	1,722
140	The International Neuroblastoma Pathology Classification (the Shimada system). , 1999, 86, 364.		2
141	Terminology and morphologic criteria of neuroblastic tumors. <i>Cancer</i> , 1999, 86, 349-363.	4.1	10
142	Pathology review of screening negative neuroblastomas. , 1998, 83, 575-581.		17
143	Screening for neuroblastoma in north america. Preliminary results of a pathology review from the quebec project. <i>Cancer</i> , 1995, 76, 2363-2371.	4.1	28
144	Identification of Subsets of Neuroblastomas by Combined Histopathologic and N-myc Analysis. <i>Journal of the National Cancer Institute</i> , 1995, 87, 1470-1476.	6.3	154

#	ARTICLE	IF	CITATIONS
145	One hundred neuroblastomas detected through a mass screening system in Japan. <i>Cancer</i> , 1994, 74, 3223-3226.	4.1	39
146	Matrix Metalloproteinases and Their Inhibitors in Tumor Progression. <i>Annals of the New York Academy of Sciences</i> , 1994, 732, 222-232.	3.8	45
147	Malignant rhabdoid tumor. A study with two established cell lines. <i>Cancer</i> , 1993, 71, 2862-2872.	4.1	85
148	Tumoral invasion in the central nervous system. <i>Journal of Neuro-Oncology</i> , 1993, 18, 111-121.	2.9	36
149	Neuroblastoma Pathology and Biology. <i>Pathology International</i> , 1992, 42, 229-241.	1.3	8
150	JC virus detection by in situ hybridization in brain tissue from elderly patients. <i>Annals of Neurology</i> , 1991, 29, 428-432.	5.3	70
151	Histopathologic features of composite ganglioneuroblastoma. Immunohistochemical distinction of the stromal component is related to prognosis. <i>Cancer</i> , 1990, 65, 255-264.	4.1	14
152	Histopathologic Prognostic Factors in Neuroblastic Tumors: Definition of Subtypes of Ganglioneuroblastoma and an Age-Linked Classification of Neuroblastomas. <i>Journal of the National Cancer Institute</i> , 1984, 73, 405-416.	6.3	796
153	A Clinicopathological Study on the Cardiac Rupture Following Myocardial Infarction in the Aged. <i>International Heart Journal</i> , 1968, 9, 265-280.	0.6	6